RBC Capital lowered the firm’s price target on Biohaven (BHVN) to $66 from $68 and keeps an Outperform rating on the shares. The firm’s price target reduction reflects the company’s higher than expected Q3 operating expense and the recent equity raise, though Biohaven also remains on track for key value inflecting readouts by the end of the year, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BHVN:
- Biohaven price target raised to $75 from $55 at TD Cowen
- Biohaven reports Q3 adjusted EPS ($1.74), consensus ($1.70)
- Biohaven options imply 19.6% move in share price post-earnings
- Biohaven price target raised to $65 from $63 at BofA
- RBC says Scholar Rock ‘win’ in SMA has favorable Biohaven implications
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
